

# CITATION REPORT

List of articles citing

Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus

DOI: 10.1191/0961203304lu1067sr  
Lupus, 2004, 13, 601-4.

**Source:** <https://exaly.com/paper-pdf/36565721/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
103	The management of pediatric systemic lupus erythematosus. <b>2005</b> , 1, 82-92		9
102	Novel approaches to therapy for systemic lupus erythematosus: update 2005. <b>2005</b> , 1, 223-38		3
101	2005 Dr. Gary J. Becker Young Investigator Award: periprocedural oral administration of the leflunomide analogue FK778 inhibits neointima formation in a double-injury rat model of restenosis. <b>2005</b> , 16, 903-10		6
100	Leflunomide: long-term clinical experience and new uses. <b>2005</b> , 6, 787-801		13
99	Therapeutic advances in systemic lupus erythematosus. <b>2006</b> , 9, 18-23		1
98	Therapeutic options for resistant lupus nephritis. <b>2006</b> , 36, 71-81		43
97	Successful treatment with leflunomide of arthritis in systemic sclerosis patients. <b>2006</b> , 45, 1175-6		9
96	Leflunomide in the treatment of rheumatoid arthritis. <b>2006</b> , 2, 17-31		7
95	Emerging drug therapies for systemic lupus erythematosus. <b>2006</b> , 11, 597-608		6
94	Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. <b>2007</b> , 66, 1026-32		56
93	Management of systemic lupus erythematosus in Chinese patients. <b>2007</b> , 3, 925-35		4
92	38 Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs. <b>2007</b> , 424-479		1
91	Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin. <b>2008</b> , 47, 83-6		22
90	Treatment of Lupus Nephritis. <b>2008</b> , 4, 140-151		
89	[Treatment of lupus nephritis]. <b>2008</b> , 4, 140-51		
88	Adalimumab-induced lupus erythematosus. <i>Lupus</i> , <b>2008</b> , 17, 676-8	2.6	20
87	Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. <i>Lupus</i> , <b>2008</b> , 17, 638-44	2.6	85

86	Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. <b>2008</b> , 47, 1367-72	15
85	Systemic Lupus Erythematosus. <b>2008</b> , 303-338	6
84	What's new in clinical trials in lupus?. <b>2009</b> , 4, 473-485	1
83	EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints. <b>2009</b> , 68, 477-83	26
82	Lupus arthritis. <b>2009</b> , 23, 495-506	79
81	The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy. <b>2009</b> , 29, 1331-5	19
80	Systemic Lupus Erythematosus. <b>2009</b> , 131-159	2
79	Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. <b>2010</b> , 62, 211-21	106
78	Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. <b>2010</b> , 2, 53-71	6
77	Contemporary treatment of systemic lupus erythematosus: an update for clinicians. <b>2010</b> , 1, 163-75	39
76	Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases. <b>2010</b> , 31, 565-88	24
75	Update on emerging drug therapies for systemic lupus erythematosus. <b>2010</b> , 15, 53-70	15
74	4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice. <b>2010</b> , 176, 2840-7	44
73	Autologous hematopoietic stem cell transplantation for childhood autoimmune disease. <b>2010</b> , 57, 239-71	26
72	Cutaneous lupus erythematosus: update of therapeutic options part II. <b>2011</b> , 65, e195-213	89
71	PHARMACOLOGY AND DRUG THERAPY. <b>2011</b> , 71-126	18
70	Current drugs in systemic lupus erythematosus. <b>2011</b> , 72, 561-572	0
69	Sjögren's Syndrome. <b>2012</b> ,	7

68	Anti citrullinated protein antibodies and mechanism of action of common disease modifying drugs--insights in pathomechanisms of autoimmunity. <b>2012</b> , 18, 4526-36		1
67	Comment traiter une arthrite rfractaire au cours du lupus?. <b>2012</b> , 79, 393-396		
66	Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. <b>2012</b> , 66, 906-9		55
65	Leflunomide in dermatology. <b>2012</b> , 66, 673-9		20
64	Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. <b>2012</b> , 142, e1S-e111S		37
63	Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. <i>Lupus</i> , <b>2012</b> , 21, 386-401	2.6	51
62	Immunosuppressive therapy for autoimmune lung diseases. <b>2012</b> , 32, 633-69		10
61	Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. <b>2012</b> , 32, 633-8		9
60	How to treat refractory arthritis in lupus?. <b>2012</b> , 79, 347-50		8
59	Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety. <b>2013</b> , 18, 615-22		9
58	Is there an effective treatment for late-onset systemic lupus erythematosus?. <b>2013</b> , 9, 437-450		
57	Lupus nephritis: treatment of resistant disease. <b>2013</b> , 8, 154-61		19
56	Leflunomide: friend or foe for systemic lupus erythematosus?. <b>2013</b> , 33, 273-6		23
55	Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. <b>2013</b> , 65, 1775-85		38
54	Immunosuppressive Drug Therapy. <b>2013</b> , 609-625		1
53	Overlap connective tissue disease syndromes. <b>2013</b> , 12, 363-73		113
52	Leflunomide: dermatologic perspective. <b>2013</b> , 24, 89-95		11
51	Systemic lupus erythematosus: a therapeutic challenge for the XXI century. <b>2014</b> , 33, 441-50		9

50	Treatment of Autoimmune Disease: Established Therapies. <b>2014</b> , 1209-1220		
49	The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis. <b>2015</b> , 10, e0144548		20
48	Etanercept in refractory lupus arthritis: An observational study. <b>2015</b> , 44, 672-9		18
47	Mesenchymal stromal cells and rheumatic disorders. <b>2015</b> , 168, 201-7		9
46	Lupus eritematoso sistémico. <b>2015</b> , 48, 1-17		
45	Systemic lupus erythematosus: review of synthetic drugs. <b>2015</b> , 16, 2793-806		14
44	Treatment of severe lupus nephritis: the new horizon. <b>2015</b> , 11, 46-61		67
43	Joint Involvement in Systemic Lupus Erythematosus. <b>2016</b> , 61-76		
42	T-cell-directed therapies in systemic lupus erythematosus. <i>Lupus</i> , <b>2016</b> , 25, 1080-5	2.6	3
41	Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management. <b>2016</b> , 146, 413.e1-413.e14		1
40	Leflunomide and teriflunomide. <b>2016</b> , 498-511		
39	[Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management]. <b>2016</b> , 146, 413.e1-14		10
38	Systemic lupus erythematosus: An update for ophthalmologists. <b>2016</b> , 61, 65-82		20
37	Trigger factors of cutaneous lupus erythematosus: a review of current literature. <i>Lupus</i> , <b>2017</b> , 26, 791-807		17
36	Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. <b>2017</b> , 76, 1575-1582		37
35	Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. <b>2017</b> , 56, i100-i113		27
34	Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review. <b>2017</b> , 47, 680-689		15
33	Nonbiologic Drugs in Pediatric Rheumatology. <b>2017</b> , 55-75		

32	S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). <b>2017</b> , 31, 389-404	75
31	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. <b>2017</b> , 958-982.e7	2
30	Desirable and Adverse Effects of Antiinflammatory Agents on the Heart. <b>2017</b> , 617-643	0
29	Systemic and Biologic Agents for Lupus Erythematosus. <b>2018</b> , 377-390	
28	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <b>2018</b> , 57, e1-e45	150
27	The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study. <b>2019</b> , 19, 351-366	10
26	Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis. <b>2019</b> , 51, 1987-1998	7
25	Medical management of wrist and hand inflammatory conditions: A literature review. <b>2019</b> , 6, 53-60	
24	A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus. <b>2019</b> , 136, 104942	5
23	Novel paradigms in systemic lupus erythematosus. <b>2019</b> , 393, 2344-2358	186
22	Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. <b>2019</b> , 39, 643-651	4
21	Immunosuppressive Drug Therapy. <b>2019</b> , 673-688	
20	Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. <b>2019</b> , 38, 859-867	12
19	The role of flavonoids in autoimmune diseases: Therapeutic updates. <b>2019</b> , 194, 107-131	70
18	Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. <b>2020</b> , 16, 32-52	36
17	Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development. <b>2020</b> , 29, 1151-1162	5
16	Candidate drug replacements for quinacrine in cutaneous lupus erythematosus. <b>2020</b> , 7,	1
15	Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review. <b>2021</b> , 93, 107398	5

- 14 Immunosuppressive therapy in SLE. **2021**, 623-659
- 13 Extraglandular Manifestations of Sjögren's Syndrome (SS): Dermatologic, Arthritic, Endocrine, Pulmonary, Cardiovascular, Gastroenterology, Renal, Urology, and Gynecologic Manifestations. **2011**, 285-316 4
- 12 Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. **2013**, 917-940.e6 2
- 11 Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus. **2020**, 5, 20
- 10 Leflunomide. **2006**, 2015-2024
- 9 Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. **2009**, 883-907 0
- 8 IMMUNE MODULATORS. **2010**, 491-598
- 7 GLUCOCORTICOIDS AND DISEASE MODIFYING ANTIRHEUMATIC DRUGS. **2010**, 371-667
- 6 Treatment of non-renal lupus. **2011**, 1307-1316.e4
- 5 Comment je traite une atteinte articulaire refractaire aux AINS ?. **2013**, 311-314
- 4 A Unified Molecular Signature of Systemic Lupus Erythematosus Revealed by Integrated, Multi-Cohort Transcriptomic Analysis.
- 3 Management of non-renal manifestations of systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. 0
- 2 Systemic Lupus Erythematosus. **2023**, 167-212 0
- 1 Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. **2023**, 22, 103312 0